Picture loading failed.

Pre-Made Serplulimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-515-1mg 1mg 3090
GMP-Bios-ab-515-10mg 10mg Inquiry
GMP-Bios-ab-515-100mg 100mg Inquiry
GMP-Bios-ab-515-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Serplulimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
INN Name Serplulimab
TargetPDCD1/PD-1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesHenlix Biotech;Shanghai Henlius Biotech
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Hepatitis B;Gastric cancer;Cervical cancer;Hepatitis B;Liver cancer;Solid tumours
Conditions Discontinuedna
Development Techna